Genomenon
Genomic Intelligence for Rare Disease and Cancer
ABOUT US
Genomenon is a genomics intelligence company in the lead position to be the first to curate the entire human genome. Our team is dedicated to improving the quality of patients’ lives by uncovering the genomic drivers of genetic disease and cancer.
Blending the power of AI with the precision of genomic expertise, Genomenon simplifies complex genetic data into actionable insights for patient diagnosis and precision medicine development.
Our solutions include:
OUR STORY
Genomenon, a name signifying “born out of need” in ancient Greek, perfectly encapsulates the genesis of our journey.
In his clinical practice and genomic research, co-founder Dr. Mark Kiel was frustrated with the painfully slow and time-consuming process of manual curation. He was also well aware of the diagnostic odyssey that thousands of rare disease patients and families face as he and his twin brother had hypodontia, or missing adult teeth, in their youth. Living with a rare condition as a child focused Mark’s attention on genetics, and his desire to make an impact on rare diseases.
Genomenon was founded in 2014 to address this pressing need for faster, more comprehensive variant interpretation by combining expert curation with unique machine-learning methods designed to keep up with the pace of new publications and present the most relevant information to researchers.
Today, Genomenon empowers scientists and researchers at pharmaceutical companies, clinical labs, and universities to more thoroughly understand diseases at a molecular level.
Genomenon is headquartered in Ann Arbor, Michigan.
MEET THE TEAM
Mike Klein CEO
With over 25 years of developing, building and growing 4 different high-tech companies, Mike raised over $50M in capital and had several successful investor exits.
Mark J. Kiel, MD, PhD CSO & Co-Founder
Mark has extensive experience in genome-sequencing and clinical data analysis underlying the vision and technology driving the Genomenon suite of software tools.
Sean Kearney CFO
Always seeking opportunities for growth, Sean has spent his career investing in and scaling innovative platforms in genomics, telemedicine and healthcare delivery.
Sam Globus, PhD COO
Sam brings a wealth of experience in genomic product development and operations to the team, and manages the rapid growth of our data science and variant curation work.
Brittnee Jones, PhD VP of Product & Product Strategy
Brittnee has spent over a decade building and leading customer success teams across the NGS space, ensuring rapid product adaption and maximal value for customers.
Jon Murray VP of Sales
Jon has been in the informatics market for over 25 years. He brings a track record of successful sales management and team building.
Colleen McMillen VP, Marketing
Colleen is an accomplished communications and marketing executive in the health space with more than two decades of experience delivering high-impact positioning for products, organizations and executive teams.
Dave Anstey VP, Pharma Business Development
Dave has almost 30 years of experience selling scientific software with a track record of building successful sales teams and meaningful customer relationships.
Jeffrey Bissonnette Senior Director of Genomic Curation
With a background in genetic counseling, Jeffrey brings over a decade of experience in clinical genetics, variant interpretation, and software tools for variant analysis.
Jonathan Eads VP, Engineering
Jonathan brings 25 years of experience in genomics, drug discovery, bioinformatics, and AI/ML software application development, with extensive experience building and leading engineering teams to deliver operational excellence.
Ronda Bergman Director of Engineering
Ronda has spent more than 20 years working in software development in a variety of roles, from strategy execution to building effective teams.
Larisa Ćerimagić Director of Services
With a background in genetics, and over a decade in variant science, Larisa manages teams that provide curation services for genomic industry leaders.
Erin McCann Head of People
Erin McCann is an HR and People leader with 20+ years’ of diverse experience. She supports startup teams through rapid growth, cultivating inclusive organizational cultures.
Kojo Elenitoba-Johnson, MD CO-FOUNDER & ADVISOR
Kojo is the Director for Precision and Computational Diagnostics at University of Pennsylvania Perelman School of Medicine and President of the Association of Molecular Pathology.
Megan Lim, MD, PhD CO-FOUNDER & ADVISOR
Megan is the Director of the Hematopathology and Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania.
Every accolade is a testament to our team and our mission to make genomic information actionable
CAREERS AT GENOMENON
Click on our current open positions to learn more and apply.
OUR CORE VALUES
Always Learning
We approach challenges with curiosity & a growth mindset to imagine what can be, not what is
Data Driven
We ask questions and look to the evidence for answers
Customer & Patient Centric
We put customers and patients first in everything that we do
Humbly Confident
We have confidence in who we are, where we're going, and how we're getting there
True Grit
We embody passion, persistence, and aren't afraid of hard work
Citing Mastermind
When citing use of the Mastermind Genomic Intelligence Platform, use the following text:
Mastermind Genomic Intelligence Platform (https://www.genomenon.com/mastermind)
Details on the Mastermind research paper published in November of 2020:
PubMed: https://pubmed.ncbi.nlm.nih.gov/33281875/
DOI: https://doi.org/10.3389/fgene.2020.577152
Citation: Chunn LM, Nefcy DC, Scouten RW, Tarpey RP, Chauhan G, Lim MS, Elenitoba-Johnson KSJ, Schwartz SA, Kiel MJ. Mastermind: A Comprehensive Genomic Association Search Engine for Empirical Evidence Curation and Genetic Variant Interpretation. Front Genet. 2020 Nov 13;11:577152. doi: 10.3389/fgene.2020.577152. PMID: 33281875; PMCID: PMC7691534.
MASTERMIND GENOMIC INTELLIGENCE PLATFORM
Say Goodbye to CTRL F
Say Goodbye to CTRL F